Armata Pharmaceuticals, Inc.
Clinical trials sponsored by Armata Pharmaceuticals, Inc., explained in plain language.
-
Virus vs. superbug: new weapon tested for dangerous blood infections
Disease control CompletedThis study tested whether adding an experimental treatment called AP-SA02 to standard antibiotics helps adults hospitalized with a serious Staphylococcus aureus (Staph) blood infection. AP-SA02 is a type of virus that specifically attacks bacteria. The main goals were to see if t…
Phase: PHASE1, PHASE2 • Sponsor: Armata Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Virus vs. superbug: inhaled phage therapy fights stubborn lung infection
Disease control CompletedThis study tested whether inhaling a special virus mixture (called AP-PA02) could safely reduce a hard-to-treat bacteria in the lungs of people with bronchiectasis. It involved 48 adults with a chronic Pseudomonas aeruginosa infection. Participants were randomly assigned to recei…
Phase: PHASE2 • Sponsor: Armata Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC